PercAssist

PercAssist is pioneering a next-generation mechanical circulatory support (MCS) device that operates from outside the heart's chambers. Its eVAD™ System is an extravascular, intrapericardial device that compresses the heart in sync with its natural rhythm, offering potential biventricular support without the need for blood contact or systemic anticoagulation. The company has completed key preclinical studies and initiated early clinical programs in Europe and South America, targeting the large and growing population of patients with cardiogenic shock and advanced heart failure. With a strong IP portfolio and an experienced leadership team, PercAssist is positioned to address significant unmet needs in the MCS market.

Extravascular direct cardiac compression via an intrapericardial device that synchronously inflates to augment native heart function, avoiding blood contact.

PercAssist competes in the MCS market against dominant players like Abiomed (Impella), Abbott (HeartMate, CentriMag), Medtronic (HeartWare), and Getinge (Cardiohelp ECMO). Its primary differentiation is the extravascular, non-blood-contacting approach, which aims to avoid the bleeding, clotting, and infection risks associated with these incumbent intravascular and intracardiac devices.